Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.

Luis Teixeira,Jacques Medioni,Ludovic Doucet,Antoine Angelergues,Stéphane Culine,Stéphane Oudard,Mara Brizard,Zineb Ghrieb,Olivier Adotevi,Caroline Laheurte,Marie-Agnès Dragon-Durey,Pierre Laurent-Puig,Jean-Jacques Kiladjian,Simon Wain-Hobson,Valérie Doppler,Remy Defrance,Julie Garibal,Thierry Huet,Pierre Langlade-Demoyen

Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.

2019

Luis Teixeira
Jacques Medioni
Ludovic Doucet
Antoine Angelergues
Stéphane Culine
Stéphane Oudard
Mara Brizard
Zineb Ghrieb
Olivier Adotevi
Caroline Laheurte
Marie-Agnès Dragon-Durey
Pierre Laurent-Puig
Jean-Jacques Kiladjian
Simon Wain-Hobson
Valérie Doppler
Remy Defrance
Julie Garibal
Thierry Huet
Pierre Langlade-Demoyen

2642Background: INVAC-1 is an optimized DNA plasmid encoding an inactive form of human Telomerase Reverse Transcriptase (hTERT), a universal tumor antigen expressed in most of human tumors with lit...

Keywords:

Cancer research
Pathology
Telomerase reverse transcriptase
Medicine
DNA vaccination
in patient
Tumor antigen
Plasmid
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations